1、Outcomes after surgical resection of thymic carcinoma: A study from a single tertiary referral centre.,宋正波,张沂平,Eur J Surg Oncol,SCI,2014-11,浙江省肿瘤医院,1区,3.379,1523-7
2、Chemotherapy and prognosis in advanced thymic carcinoma patients,程国平,宋正波,Clinics ,SCI,2015-12,浙江省肿瘤医院,3区,1.127,775-80
3、De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.,宋正波,张沂平,Clin Lung Cancer,SCI,2019-03-01 00:05,浙江省肿瘤医院,2区,4.117,:e171-e176
4、Molecular Profiling and Survival of Completely Resected Primary Pulmonary Neuroendocrine Carcinoma.,娄广媛,宋正波,Clin Lung Cancer,SCI,2017-05,浙江省肿瘤医院,2区,4.117,e197-e201
5、Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients,宋正波,张沂平,Lung Cancer,SCI,2019-08,浙江省肿瘤医院,2区,4.59,23-29
6、Intracavitary chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is not superior to TKI monotherapy in controlling malignant pleural effusion recurrence in EGFR-mutated lung cancer patients.,王文娴,宋正波,J Thorac Dis,SCI,2019-08,浙江省肿瘤医院,3区,2.07,3712-3720
7、High accuracy detection of malignant pleural effusion based on label-free surface-enhanced Raman spectroscopy and multivariate statistical analysis.,刘开元,宋正波,Spectrochim Acta A Mol Biomol Spectrosc,SCI,2019-08,浙江省肿瘤医院,4区,2.9,117632
8、Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.,王文娴,宋正波,J Transl Med,SCI,2019-02,浙江省肿瘤医院,2区,4.098,52
9、Rare frequency of gene variation and survival analysis in thymic epithelial tumors.,宋正波,张沂平,Onco Targets Ther,SCI,2016-10,浙江省肿瘤医院,2区,3.04,337-6342
10、Efficacy of pemetrexed-based regimen in relapsed advanced thymic epithelial tumors and its association with thymidylate synthetase level.,钱新宇,宋正波,Onco Targets Ther,SCI,2016-07,浙江省肿瘤医院,2区,3.04,4527-31
11、Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer,宋正波,张沂平,Arch Med Sci,SCI,2015-03,浙江省肿瘤医院,2区,2.38,164-8
12、Treatment and prognosis after progression in long-term responders to EGFR-tyrosine kinase inhibitor in advanced non-small cell lung cancer,宋正波,张沂平,Arch Med Sci,SCI,2016-02,浙江省肿瘤医院,2区,2.38,107-11
13、Genomic alterations and survival in young patients aged under 40 years with completely resected non-small cell lung cancer,杨士峰,宋正波,Ann Transl Med,SCI,2019-04,浙江省肿瘤医院,2区,3.69,140
14、Treatment and prognosis of type B2 thymoma,宋正波,张沂平,World J Surg Oncol,SCI,2014-09,浙江省肿瘤医院,2区,1.966,291
15、Patients with ROS1 rearrangement-positive non-small-cell lung cancer benefit from pemetrexed-based chemotherapy,宋正波,张沂平,Cancer Med,SCI,2019-08,浙江省肿瘤医院,2区,3.357,2688-2693
16、Mutation and prognostic analyses of PIK3CA in patients with completely resected lung adenocarcinoma,宋正波,张沂平,Cancer Med,SCI,2016-10,浙江省肿瘤医院,2区,3.357,2694-2700
17、Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.,宋正波,张沂平,Cancer Biol Ther,SCI,2017-11,浙江省肿瘤医院,3区,2.879,883-887
18、HER2 mutations in Chinese patients with non-small cell lung cancer,宋正波,张沂平,Oncotarget,SCI,2016-11,浙江省肿瘤医院,2区,5.168,78152-78158
19、ALK and ROS1 rearrangements, coexistence and treatment in epidermal growth factor receptor-wild type lung adenocarcinoma: a multicenter study of 732 cases,宋正波,张沂平,J Thorac Dis,SCI,2017-10,浙江省肿瘤医院,3区,2.027,3919-3926
20、MET Gene Amplification and Overexpression in Chinese NoneSmall-Cell Lung Cancer Patients Without EGFR Mutations,宋正波,张沂平,Clin Lung Cancer,SCI,2017-03,浙江省肿瘤医院,2区,4.117,213-219
21、Fas signaling-mediated TH9 cell differentiation favors bowel inflammation and antitumor functions,沈颖颖/宋正波,蔡志坚,Nat Commun,SCI,2019-07,浙江省肿瘤医院,1区,11.878,2924
22、Second-line docetaxel-based chemotherapy after failure of fluorouracil-based first-line treatment for advanced esophageal squamous cell carcinoma,宋正波,张沂平,Onco Targets Ther,SCI,2014-10,浙江省肿瘤医院,2区,3.046,1875-81
23、Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations,陈丹,宋正波,Onco Targets Ther,SCI,2016-07,浙江省肿瘤医院,2区,3.046,4181-6
24、Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma,宋正波,张沂平,J Transl Med,SCI,2016-06,浙江省肿瘤医院,2区,4.098,188
25、Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma,宋正波,张沂平, Lung Cancer,SCI,2016-09,浙江省肿瘤医院,2区,4.59,66-71
26、Effective treatment with icotinib in primary adenoid cystic carcinoma of the lung with liver metastasis,宋正波,张沂平,J Thorac Oncol,SCI,2014-09,浙江省肿瘤医院,3区,12.46,e67-9
27、Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer,宋正波,张沂平,Lung Cancer,SCI,2018-04,浙江省肿瘤医院,2区,4.59,57-61
28、Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma,宋正波,张沂平,Lung Cancer,SCI,2019-08,浙江省肿瘤医院,2区,4.59,16-21
29、Salvage treatment with apatinib for advanced non-small-cell lung cancer,宋正波,张沂平,Onco Targets Ther.,SCI,2017-03,浙江省肿瘤医院,2区,3.06,1821-1825
30、Liquid biopsies using pleural effusion-derived exosomal DNA in advanced lung adenocarcinoma.,宋正波,张沂平,Transl Lung Cancer Res,SCI,2019-08,浙江省肿瘤医院,1区,4.89,392-400
|